Keros Therapeutics, Inc.KROSNASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank100
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
29.55%
↑ 100% vs avg
Percentile
P100
Near historical high
Streak
2 yr
Consecutive growthExpanding
Average
-15198.77%
Historical baseline
PeriodValueYoY Change
202529.55%+100.6%
2024-5234.48%+94.8%
2023-100779.47%-
20220.00%+100.0%
2021-280.35%-135.8%
2019-118.90%-1436.2%
2018-7.74%-